Results of migraine treatment depending on its menstrual association
| العنوان: | Results of migraine treatment depending on its menstrual association |
|---|---|
| المؤلفون: | E. A. Kiryanova, N. A. Kovalchuk, G. R. Tabeeva |
| المصدر: | Медицинский совет, Vol 0, Iss 12, Pp 426-432 (2021) |
| بيانات النشر: | Remedium, Ltd., 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_specialty, business.industry, menstrual-related migraine, media_common.quotation_subject, monoclonal antibodies to calcitoningene-related peptide receptor / ligand, Mean age, Menstrual migraine, General Medicine, Triptans, medicine.disease, medication-overuse headache, menstrual migraine, Migraine, migraine without aura, Internal medicine, medicine, Medicine, business, Standard therapy, Menstrual cycle, media_common, medicine.drug |
| الوصف: | Introduction. Menstrual migraine attacks are considered more intense, prolonged, and resistant to treatment than non-menstrual ones. Currently, effect of preventive therapy on the course of menstrual-associated migraine has not been well studied; there are isolated studies on the beneficial effect of hormonal therapy on these attacks.The aim of the study was to compare the treatment results in the groups of menstrual-associated and non-menstrual migraine.Materials and methods. This comparative study included 91 patients aged 18 to 48 years (mean age 33,82 ± 8.4) with migraine and menstrual cycle. Depending on the menstrual association of migraine attacks, the patients were divided into 2 groups: group 1 – 54 patients (mean age 36.07 ± 7.37 years) with menstrual-associated migraine (MAM); group 2 – 37 patients (mean age 30.46 ± 8.81 years) with non-menstrual migraine (NMM).Results. Patients with MAM had more migraine days per month, more often received therapy associated with medication-overuse headache (MOH), more often had experience with triptans in comparison with NMM patients. After the treatment, the number of days with migraine per month in the MAM group remained more than in the NMM group: 8 or more days per month were noted in 36.4%, while among NMM patients – 10.8%. The transition to the new therapy with monoclonal antibodies to the CGRP receptor / ligand was positively assessed by 42.9% of MAM patients and 8.1% of NMM patients. Increased duration of hormonal therapy was characterized by a decrease in the number of days with migraines per month (cor = -0,28).Conclusion. In the MAM group, more severe diseases and frequent formation of MOH are observed, as well as a higher resistance to therapy than in NMM. In general, the use of standard therapy regimens for MAM is less effective than for NMM. |
| تدمد: | 2658-5790 2079-701X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da507793088169b1d9f34a9a4b5e1c1bTest https://doi.org/10.21518/2079-701x-2021-12-426-432Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....da507793088169b1d9f34a9a4b5e1c1b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 26585790 2079701X |
|---|